Connect with us

BUSINESS

Dr. Reddy’s to introduce Sanofi’s novel RSV drug in India 

Published

on

Dr. Reddy’s to introduce Sanofi’s novel RSV drug in India 


Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Containing monoclonal antibody nirsevimab in a prefilled injection, Beyfortus is used for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season.

Dr. Reddy’s will get exclusive rights from SHIPL to promote and distribute Beyfortus. The announcement follows an exclusive distribution partnership it had forged for Sanofi portfolio of vaccines in India last year. Beyfortus is expected to be launched in the second quarter of the current fiscal year, the Hyderabad-based pharma major said.

RSV is a highly contagious virus that can lead to serious respiratory illness for infants. In addition to being the most common cause of LRTD such as bronchiolitis and pneumonia in infants, it is also a leading cause of hospitalisation in infants worldwide, with most hospitalisations occurring in healthy infants born at term. In 2019, there were approximately 33 million cases of acute lower respiratory infections globally, leading to more than 3 million hospitalisations, and it was estimated that there were 26,300 in-hospital deaths of children younger than 5 years, Dr.Reddy’s said in a release.

Launch of Beyfortus will help strengthen its immunisation portfolio in India, CEO-Branded Markets (India and Emerging Markets) M.V. Ramana said.

Beyfortus, which has been approved for use in the EU, the U.S., China, Japan and many other countries, received marketing authorisation approval in India from the Central Drugs Standard Control Organization (CDSCO) in June.

“In India, where the disease burden is significant and early protection is critical, this collaboration with Dr. Reddy’s enables us to reach parents and healthcare providers with an innovative solution,” Head of Sanofi Vaccines (India) Nitya Padmanabhan said.



Source link

Continue Reading
Comments

BUSINESS

Gold has proved your grandmother right – Times of India

Published

on


Had you listened to your grandmother and bought gold on Akshaya Tritiya, your investment would have earned handsome returns. Rising geopolitical tensions and widespread economic uncertainty have pushed gold prices to almost Rs 10,000 per gram. Gold bought on this auspicious day has delivered double-digit returns in the past 25 years.
A substantial portion of these returns is attributable to the dramatic rise in gold prices in the past four years. Gold prices have more than doubled from Rs 47,452 per 10 grams in April 2021 to Rs 98,955 now. Investments in the yellow metal since 2021 have yielded more than 20 per cent returns. That’s more than what equity funds have delivered in the past four years.
However, though gold prices have moved up smartly, the yellow metal has also witnessed extended periods of muted returns. Between 2014 and 2018, the annualised return from gold was less than 2 per cent. Gold could not even beat the 4.8 per cent annual consumer inflation during that period.
Many financial advisors consider gold a dead investment that doesn’t generate any income or pay dividends. While that is true to some extent, gold is an excellent diversification tool because its price is not linked with other asset classes. During a geopolitical crisis or periods of high inflation, equities tend to do poorly. But these conditions are good for gold. The negative correlation reduces the portfolio risk.Gold is also a very liquid asset and can be bought and sold across global markets.
Experts forecast a further upside in 2025. Geopolitical tensions have only increased, and the new occupant in the White House has triggered a worldwide tariff war.
Even so, don’t look at gold as a speculative bet. Rather, treat it as a wealth preservation tool and portfolio diversifier. Experts advise that investors should not put more than 15-20 per cent of their overall portfolio in the yellow metal.
With gold hitting Rs 1 lakh per 10 grams, many investors may be thinking of booking profits. With the removal of the indexation benefit in 2023, gains from gold are now added to the income of the investor and taxed at normal rates.
But Sovereign Gold Bonds (SGBs) offer a unique tax advantage to investors. SGBs are issued by the RBI, and their prices are linked to the price of gold. Investors get 2.5 per cent interest every year, which is fully taxable. But if SGBs are held till maturity, the capital gains from the investment are tax-free.

Year Akshaya Tritiya Date Gold Price (Rs/10 gm) CAGR Till Date* (%)
2000 6-May-00 4,355 13.3
2001 26-Apr-01 4,025 14.3
2002 16-May-02 4,827 14.0
2003 6-May-03 5,310 14.2
2004 23-Apr-04 5,713 14.5
2005 11-May-05 6,113 14.9
2006 30-Apr-06 9,520 13.1
2007 20-Apr-07 9,352 14.0
2008 8-May-08 11,726 13.4
2009 27-Apr-09 14,792 12.6
2010 15-May-10 18,177 12.0
2011 6-May-11 22,000 11.3
2012 24-Apr-12 29,055 9.9
2013 13-May-13 26,890 11.5
2014 2-May-14 29,480 11.6
2015 21-Apr-15 26,950 13.9
2016 9-May-16 30,330 14.0
2017 28-Apr-17 29,620 16.3
2018 18-Apr-18 (Wednesday) 31,410 17.8
2019 7-May-19 (Tuesday) 31,739 20.9
2020 26-Apr-20 (Sunday) 46,353 16.4
2021 14-May-21 (Friday) 47,452 20.2
2022 3-May-22 (Tuesday) 52,670 23.4
2023 22-Apr-23 (Saturday) 61,080 27.3
2024 10-May-24 (Friday) 73,240 35.1





Source link

Continue Reading

BUSINESS

Urban Company files for Rs 1,900 crore IPO with Sebi – Times of India

Published

on


Urban Company files draft papers for IPO

NEW DELHI: Urban Company has filed draft papers with the Securities and Exchange Board of India (Sebi) for an initial public offering (IPO) to raise Rs 1,900 crore. According to its Draft Red Herring Prospectus (DRHP), the IPO will comprise a fresh issue of shares worth Rs 429 crore and an offer for sale (OFS) of shares worth Rs 1,471 crore by existing investors.
Key OFS participants include Accel India, Elevation Capital, Bessemer India Capital Holdings II Ltd, Internet Fund V Pte. Ltd, and VYC11 Ltd.
The company plans to utilise the proceeds to fund technological upgrades and cloud infrastructure (Rs 190 crore), lease payments for new office spaces (Rs 70 crore), marketing initiatives (Rs 80 crore), and for general corporate purposes.
Kotak Mahindra Capital Company, Morgan Stanley India Company, Goldman Sachs (India) Securities, and JM Financial are acting as the book-running lead managers for the IPO.
Urban Company operates a technology-driven online marketplace offering home and beauty services. As of December 31, 2024, it had a presence in 59 cities across India, the United Arab Emirates, Singapore, and Saudi Arabia, including 48 locations within India.
The platform enables consumers to book a wide range of services such as cleaning, pest control, electrical and plumbing work, carpentry, appliance servicing and repair, painting, skincare, hair grooming, and massage therapy, with services delivered by independent professionals.





Source link

Continue Reading

BUSINESS

Central Bank of India net profit rises 28%

Published

on


Central Bank of India Q4 net profit increased 28% to ₹ 1,034 crore from ₹807 crore in the year-ago period. The company’s net interest income, however, contracted 4% to ₹3,399 crore in the reporting quarter. The net interest margin also dipped to 3.17% in the quarter ended March 2025, as against 3.6% in the corresponding period last fiscal. The gross NPAs improved to 3.2% and net NPA to 0.5% from 4.5% and 1.2% respectively. The bank expanded net profit by 48.5% to ₹3,785 crore in fiscal 2024-25 from ₹2,549 crore in FY24.



Source link

Continue Reading

Trending

Copyright © 2025 Republic Diary. All rights reserved.

Exit mobile version